Results also indicate dual treatment of ZB131 with standard-of-care chemotherapy gemcitabine enhances suppression of tumor growth above chemotherapy alone in cholangiocarcinoma.

First-in-human, open-label, dose escalation study will evaluate ZB131 in patients who have solid tumors with high CSP expression.